Using genetics and genomics strategies to personalize therapy for cancer: focus on melanoma.

[1]  K. Flaherty,et al.  Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  T. H. Sasongko,et al.  Tuberous Sclerosis Complex , 2010, A Practical Approach to Stereo EEG.

[3]  A. Dobrovic,et al.  Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure , 2010, Pigment cell & melanoma research.

[4]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[5]  Yusuke Nakamura,et al.  Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Pui,et al.  Adult acute lymphoblastic leukemia , 2010, Cancer.

[7]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[8]  Tom Royce,et al.  A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.

[9]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[10]  D. Weghuis,et al.  Identification of chromosomal abnormalities relevant to prognosis in chronic lymphocytic leukemia using multiplex ligation-dependent probe amplification. , 2009, Cancer genetics and cytogenetics.

[11]  Keith L. Ligon,et al.  Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples , 2009, PloS one.

[12]  P. Ascierto,et al.  Clinical genetic testing for familial melanoma in Italy: a cooperative study. , 2009, Journal of the American Academy of Dermatology.

[13]  M. Beckmann,et al.  Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. , 2009, JAMA.

[14]  T. Ahern,et al.  No Increase in Breast Cancer Recurrence with Concurrent Use of Tamoxifen and Some CYP2D6-Inhibiting Medications , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[15]  M. Richard,et al.  Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues. , 2009, Analytical biochemistry.

[16]  Yiling Lu,et al.  AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. , 2009, Cancer cell.

[17]  E. Zwarthoff,et al.  A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene , 2009, BMC Research Notes.

[18]  L. Saltz,et al.  Evolving treatment of advanced colon cancer. , 2009, Annual review of medicine.

[19]  E. Hayden.  Personalized cancer therapy gets closer , 2009, Nature.

[20]  M. Gulley,et al.  A Rational Approach to Genetic Testing for Sarcoma , 2009, Diagnostic molecular pathology (Print).

[21]  S. Landi.  Genetic predisposition and environmental risk factors to pancreatic cancer: A review of the literature. , 2009, Mutation research.

[22]  D. Hayes,et al.  Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing? , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[23]  J. Riemann,et al.  Pancreatic cancer screening: state of the art , 2009, Expert review of gastroenterology & hepatology.

[24]  H. Guchelaar,et al.  Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer , 2009, Clinical Cancer Research.

[25]  D. Kwiatkowski,et al.  New applications and developments in the use of multiplex ligation‐dependent probe amplification , 2008, Electrophoresis.

[26]  Susan Muller,et al.  KIT Gene Mutations and Copy Number in Melanoma Subtypes , 2008, Clinical Cancer Research.

[27]  Amy E. Hawkins,et al.  DNA sequencing of a cytogenetically normal acute myeloid leukemia genome , 2008, Nature.

[28]  M. Malafa,et al.  Early detection of pancreatic cancer: why, who, and how to screen. , 2008, Cancer control : journal of the Moffitt Cancer Center.

[29]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[30]  T. Rebbeck,et al.  The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. , 2008, Cancer research.

[31]  Hong Wu,et al.  Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas , 2008, Molecular Cancer Therapeutics.

[32]  Alan Ashworth,et al.  A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  T. Mak,et al.  Pten deficiency in melanocytes results in resistance to hair graying and susceptibility to carcinogen-induced melanomagenesis. , 2008, Cancer research.

[34]  P. Jänne,et al.  Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients , 2008, British Journal of Cancer.

[35]  L. Aspinwall,et al.  CDKN2A/p16 Genetic Test Reporting Improves Early Detection Intentions and Practices in High-Risk Melanoma Families , 2008, Cancer Epidemiology Biomarkers & Prevention.

[36]  R. Berbeco,et al.  Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing , 2008, Nature Medicine.

[37]  G. Doherty,et al.  Multiple endocrine neoplasia. , 2008, Surgical oncology clinics of North America.

[38]  K. Flaherty,et al.  The MAPK pathway in melanoma , 2008, Current Opinion in Oncology.

[39]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[40]  A. Kallioniemi.  CGH microarrays and cancer. , 2008, Current opinion in biotechnology.

[41]  F. Elmslie,et al.  Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. , 2008, The New England journal of medicine.

[42]  E. Thiele,et al.  Efficacy of sirolimus in treating tuberous sclerosis and lymphangioleiomyomatosis. , 2008, The New England journal of medicine.

[43]  V. Schmithorst,et al.  Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. , 2008, The New England journal of medicine.

[44]  Wolfgang Simon,et al.  Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[46]  S. Gabriel,et al.  High-throughput oncogene mutation profiling in human cancer , 2007, Nature Genetics.

[47]  K. Pacak,et al.  Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. , 2007, The Journal of clinical endocrinology and metabolism.

[48]  S. Puig,et al.  High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. , 2006, Cancer research.

[49]  S. Gruber,et al.  ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  S. Puig,et al.  Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents , 2006, Journal of Medical Genetics.

[51]  J. Ragoussis,et al.  Matrix-Assisted Laser Desorption/Ionisation, Time-of-Flight Mass Spectrometry in Genomics Research , 2006, PLoS genetics.

[52]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[53]  V. A. Flørenes,et al.  Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome. , 2005, American journal of clinical pathology.

[54]  M. Loda,et al.  Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. , 2005, The Journal of molecular diagnostics : JMD.

[55]  D. Polsky,et al.  PTEN Expression in Melanoma: Relationship with Patient Survival, Bcl-2 Expression, and Proliferation , 2005, Clinical Cancer Research.

[56]  M. Rhodes,et al.  Assessment of two flexible and compatible SNP genotyping platforms: TaqMan SNP Genotyping Assays and the SNPlex Genotyping System. , 2005, Mutation research.

[57]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[58]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[59]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[60]  C. Eng,et al.  Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. , 2004, JAMA.

[61]  P. Schofield,et al.  The prevalence of SDHB, SDHC, and SDHD mutations in patients with head and neck paraganglioma and association of mutations with clinical features , 2004, Journal of Medical Genetics.

[62]  C. Springer,et al.  V599EB-RAF is an Oncogene in Melanocytes , 2004, Cancer Research.

[63]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[64]  M. Mihm,et al.  PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma. , 2003, Journal of the American Academy of Dermatology.

[65]  G. Robertson,et al.  Loss of PTEN promotes tumor development in malignant melanoma. , 2003, Cancer research.

[66]  L. Chin,et al.  The INK4a/ARF locus and melanoma , 2003, Oncogene.

[67]  L. V. van't Veer,et al.  Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. , 2003, Cancer research.

[68]  Richard Wooster,et al.  BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.

[69]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[70]  D. Zwijnenburg,et al.  Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. , 2002, Nucleic acids research.

[71]  J. Schipper,et al.  Germ-line mutations in nonsyndromic pheochromocytoma. , 2002, The New England journal of medicine.

[72]  N. Hayward,et al.  Nuclear PTEN expression and clinicopathologic features in a population‐based series of primary cutaneous melanoma , 2002, International journal of cancer.

[73]  J. Cowell,et al.  Application of oligonucleotides arrays for coincident comparative genomic hybridization, ploidy status and loss of heterozygosity studies in human cancers. , 2009, Methods in molecular biology.

[74]  C. Warneke,et al.  Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. , 2006, The Journal of investigative dermatology.